Patents by Inventor Rhett M. Schiffman

Rhett M. Schiffman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NON-IRRITATING TESTOSTERONE EMULSIONS
    Publication number: 20180221388
    Abstract: Disclosed herein are emulsions comprising testosterone or related androgens, castor oil, cyclodextrin, Pemulen TR-2, Polyoxyl 40, and other ingredients. The compositions are useful for treating keratoconjunctivitis sicca and meibomian gland disease.
    Type: Application
    Filed: April 9, 2018
    Publication date: August 9, 2018
    Inventors: John T. Trogden, Adnan K. Salameh, Chetan P. Pujara, Anuradha V. Gore, Jaya Giyanani, Andrea S. Kim, Mayssa Attar, Ronald Bradford, Rhett M. Schiffman
  • Non-irritating testosterone emulsions
    Patent number: 9937188
    Abstract: Disclosed herein are emulsions comprising testosterone or related androgens, castor oil, cyclodextrin, Pemulen TR-2, Polyoxyl 40, and other ingredients. The compositions are useful for treating keratoconjunctivitis sicca and meibomian gland disease.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: April 10, 2018
    Assignee: Allergan, Inc.
    Inventors: John T. Trogden, Adnan K. Salameh, Chetan P. Pujara, Anuradha V. Gore, Jaya Giyanani, Andrea S. Kim, Mayssa Attar, Ronald Bradford, Rhett M. Schiffman
  • CYCLOSPORIN COMPOSITIONS
    Publication number: 20170143792
    Abstract: Disclosed herein are therapeutic methods, compositions, and medicaments related to cyclosporine.
    Type: Application
    Filed: February 6, 2017
    Publication date: May 25, 2017
    Inventors: Richard S. Graham, Walter L. Tien, Mayssa Attar, Rhett M. Schiffman, Aileen Morgan
  • INTRACAMERAL SUSTAINED RELEASE THERAPEUTIC AGENT IMPLANTS
    Publication number: 20170071853
    Abstract: Described herein are intracameral implants including at least one therapeutic agent for treatment of at least one ocular condition. The implants described herein are not anchored to the ocular tissue, but rather are held in place by currents and gravity present in the anterior chamber of an eye. The implants are preferably polymeric, biodegradable and provide sustained release of at least one therapeutic agent to both the trabecular meshwork and associated ocular tissue and the fluids within the anterior chamber of an eye.
    Type: Application
    Filed: November 28, 2016
    Publication date: March 16, 2017
    Inventors: Michael R. Robinson, James A. Burke, Rhett M Schiffman, Alazar N. Ghebremeskel
  • Prostaglandin and vasoconstrictor pharmaceutical compositions and methods of use
    Patent number: 9579328
    Abstract: Compositions containing a prostaglandin agent and a vasoconstrictor agent for ophthalmic applications are provided as well as methods of treating ophthalmic diseases using the same. In certain embodiments, the compositions and methods are useful for treating glaucoma without causing conjunctival hyperemia.
    Type: Grant
    Filed: January 7, 2016
    Date of Patent: February 28, 2017
    Assignee: ALLERGAN, INC.
    Inventors: Rhett M. Schiffman, June Chen
  • PROSTAGLANDIN AND VASOCONSTRICTOR PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE
    Publication number: 20160354383
    Abstract: Compositions containing a prostaglandin agent and a vasoconstrictor agent for ophthalmic applications are provided as well as methods of treating ophthalmic diseases using the same. In certain embodiments, the compositions and methods are useful for treating glaucoma without causing conjunctival hyperemia.
    Type: Application
    Filed: January 7, 2016
    Publication date: December 8, 2016
    Inventors: RHETT M. SCHIFFMAN, JUNE CHEN
  • ENHANCED BIMATOPROST OPHTHALMIC SOLUTION
    Publication number: 20160354384
    Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
    Type: Application
    Filed: May 5, 2016
    Publication date: December 8, 2016
    Inventors: CHIN-MING CHANG, JAMES N. CHANG, RHETT M. SCHIFFMAN, R. SCOTT JORDAN, JOAN-EN CHANG-LIN
  • Intracameral sustained release therapeutic agent implants
    Patent number: 9504696
    Abstract: Described herein are intracameral implants including at least one therapeutic agent for treatment of at least one ocular condition. The implants described herein are not anchored to the ocular tissue, but rather are held in place by currents and gravity present in the anterior chamber of an eye. The implants are preferably polymeric, biodegradable and provide sustained release of at least one therapeutic agent to both the trabecular meshwork and associated ocular tissue and the fluids within the anterior chamber of an eye.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: November 29, 2016
    Assignee: Allergan, Inc.
    Inventors: Michael R. Robinson, James A. Burke, Rhett M. Schiffman, Alazar N. Ghebremeskel
  • ENHANCED BIMATOPROST OPHTHALMIC SOLUTION
    Publication number: 20160250225
    Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
    Type: Application
    Filed: October 6, 2015
    Publication date: September 1, 2016
    Inventors: Chin-Ming Chang, James N. Chang, Rhett M. Schiffman, R. Scott Jordan, Joan-En Chang-Lin
  • KETOROLAC TROMETHAMINE COMPOSITIONS FOR TREATING OR PREVENTING OCULAR PAIN
    Publication number: 20160243078
    Abstract: The present invention provides an aqueous ophthalmic solution comprising an effective amount of ketorolac which comprises carboxymethyl cellulose in an aqueous solution which provides increased visual acuity in users and wherein said concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a patient which is at least 130% greater than the absorption of a comparative aqueous ketorolac ophthalmic solution having the same concentration of ketorolac.
    Type: Application
    Filed: October 16, 2015
    Publication date: August 25, 2016
    Inventors: Eldon Quinn Farnes, Mayassa Attar, Rhett M. Schiffman, Chin-Ming Chang, Richard S. Graham, Devin F. Welty
  • Prostaglandin and vasoconstrictor pharmaceutical compositions and methods of use
    Patent number: 9248135
    Abstract: Compositions containing a prostaglandin agent and a vasoconstrictor agent for ophthalmic applications are provided as well as methods of treating ophthalmic diseases using the same. In certain embodiments, the compositions and methods are useful for treating glaucoma without causing conjunctival hyperemia.
    Type: Grant
    Filed: April 23, 2013
    Date of Patent: February 2, 2016
    Assignee: Allergan, Inc.
    Inventors: Rhett M. Schiffman, June Chen
  • Enhanced bimatoprost ophthalmic solution
    Patent number: 9241918
    Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
    Type: Grant
    Filed: March 4, 2010
    Date of Patent: January 26, 2016
    Assignee: Allergan, Inc.
    Inventors: Chin-Ming Chang, James N. Chang, Rhett M. Schiffman, R. Scott Jordan, Joan-En Chang-Lin
  • ENHANCED BIMATOPROST OPHTHALMIC SOLUTION
    Publication number: 20160015717
    Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
    Type: Application
    Filed: February 27, 2015
    Publication date: January 21, 2016
    Inventors: CHIN-MING CHANG, JAMES N. CHANG, RHETT M. SCHIFFMAN, R. SCOTT JORDAN, JOAN-EN CHANG-LIN
  • METHOD OF TREATING ALLERGIC CONJUNCTIVITIS WITH CYCLOSPORIN COMPOSITIONS
    Publication number: 20150366799
    Abstract: Disclosed herein is a method of treating allergic conjunctivitis, the method comprising the step of topically administering to an eye affected with such a condition a composition comprising cyclosporin, at a concentration between about 0.001% (w/v) to about 0.01% (w/v).
    Type: Application
    Filed: August 27, 2015
    Publication date: December 24, 2015
    Inventors: Aileen Morgan, Rhett M. Schiffman
  • Ketorolac tromethamine compositions for treating or preventing ocular pain
    Patent number: 9192571
    Abstract: The present invention provides an aqueous ophthalmic solution with an effective amount of ketorolac and carboxymethyl cellulose in an aqueous solution which provides increased visual acuity and wherein the concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a patient that is at least 130% greater than the absorption of a comparative aqueous ketorolac ophthalmic solution having the same concentration of ketorolac.
    Type: Grant
    Filed: September 1, 2009
    Date of Patent: November 24, 2015
    Assignee: Allergan, Inc.
    Inventors: Eldon Q. Farnes, Mayssa Attar, Rhett M. Schiffman, Chin-Ming Chang, Richard S. Graham, Devin F. Welty
  • Enhanced bimatoprost ophthalmic solution
    Patent number: 9155716
    Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: October 13, 2015
    Assignee: Allergan, Inc.
    Inventors: Chin-Ming Chang, James N. Chang, Rhett M. Schiffman, R. Scott Jordan, Joan-En Chang-Lin
  • INTRACMERAL SUSTAINED RELEASE THERAPEUTIC AGENT IMPLANTS
    Publication number: 20150283150
    Abstract: Described herein are intracameral implants including at least one therapeutic agent for treatment of at least one ocular condition. The implants described herein are not anchored to the ocular tissue, but rather are held in place by currents and gravity present in the anterior chamber of an eye. The implants are preferably polymeric, biodegradable and provide sustained release of at least one therapeutic agent to both the trabecular meshwork and associated ocular tissue and the fluids within the anterior chamber of an eye.
    Type: Application
    Filed: June 22, 2015
    Publication date: October 8, 2015
    Inventors: Michael R. Robinson, James A. Burke, Rhett M. Schiffman, Alazar N. Ghebremeskel
  • KETOROLAC-CONTAINING SUSTAINED RELEASE DRUG DELIVERY SYSTEMS
    Publication number: 20150272877
    Abstract: Biodegradable intraocular and intraarticular drug delivery systems comprising ketorolac and a biodegradable polymer matrix that can release ketorolac into an eye or joint for an extended period of time are described. The drug delivery systems may be in the form of an extruded implant and may be used to treat one or more medical and ocular conditions, such as post-operative pain and inflammation following an ocular surgery such as cataract surgery.
    Type: Application
    Filed: October 24, 2013
    Publication date: October 1, 2015
    Inventors: Ruiwen Shi, Patrick M. Hughes, Rhett M. Schiffman
  • Compositions for enhancing nail growth
    Patent number: 9101550
    Abstract: The present invention is directed to compositions and methods for stimulating the growth of nails and cuticles in a mammal, including humans. The compositions may be administered topically to the nail bed, nail matrix and cuticle in an amount effective to increase nail growth and thicken, strengthen and smooth the nail. The composition is also effective in strengthening and growing nails, including fingernails and toenails.
    Type: Grant
    Filed: January 22, 2013
    Date of Patent: August 11, 2015
    Assignee: Allergan, Inc.
    Inventors: Scott M. Whitcup, Rhett M. Schiffman, John G. Walt, Debbie D. Mullins, Connie M. Stucker
  • Intracameral sustained release therapeutic agent implants
    Patent number: 9061065
    Abstract: Described herein are intracameral implants including at least one therapeutic agent for treatment of at least one ocular condition. The implants described herein are not anchored to the ocular tissue, but rather are held in place by currents and gravity present in the anterior chamber of an eye. The implants are preferably polymeric, biodegradable and provide sustained release of at least one therapeutic agent to both the trabecular meshwork and associated ocular tissue and the fluids within the anterior chamber of an eye.
    Type: Grant
    Filed: September 19, 2013
    Date of Patent: June 23, 2015
    Assignee: Allergan, Inc.
    Inventors: Michael R. Robinson, James A. Burke, Rhett M. Schiffman, Alazar N. Ghebremeskel